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ABSTRACT
Background: In Scandinavia, there is a strong tradition for research and quality monitoring based on
registry data. In Denmark, Norway and Sweden, 63 clinical registries collect data on disease character-
istics, treatment and outcome of various cancer diagnoses and groups based on process-related and
outcome-related variables.
Aim: We describe the cancer-related clinical registries, compare organizational structures and quality
indicators and provide examples of how these registries have been used to monitor clinical perform-
ance, develop prediction models, assess outcome and provide quality benchmarks. Further, we define
unmet needs such as inclusion of patient-reported outcome variables, harmonization of variables and
barriers for data sharing.
Results and conclusions: The clinical registry framework provides an empirical basis for evidence-
based development of high-quality and equitable cancer care. The registries can be used to follow
implementation of new treatment principles and monitor patterns of care across geographical areas
and patient groups. At the same time, the lessons learnt suggest that further developments and
coordination are needed to utilize the full potential of the registry initiative in cancer care.
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In Scandinavia, there is a strong tradition for registry-based
research and health care development based on monitoring
of quality variables. Some of the first national, population-
based cancer registries with data on incident primary malig-
nancies were started here. The first registry was initiated in
Denmark in 1943, followed by Norway and Finland in 1952,
Iceland in 1954, Sweden in 1958 and later cancer registries
were also developed for Greenland in 1973 and for the Faroe
Islands in 1966 [1,2]. Based on these registries, cancer statis-
tics for more than 50 cancer types are collected in the inter-
active NORDCAN database that allows calculations of e.g.,
incidence, prevalence, and relative survival on national and
regional levels [3].
Denmark, Norway and Sweden have over the past two
decades invested massively in the establishment of comple-
mentary clinical registries, also referred to as quality registries
or clinical quality registries, with 248 such registries currently
available for various diseases [4]. In cancer care, quality
parameters are reported into 25 Danish, 8 Norwegian and 30
Swedish diagnosis-specific clinical registries. Additionally, all
three countries have special registries for cancer screening
and in Denmark and in Sweden data from specialized pallia-
tive care are captures into palliative care registries. The clin-
ical registries provide real-time data to follow
implementation of evidence-based principles of care, monitor
quality of care and contribute to high quality care and equity
in care [5]. These registries also constitute an empirical basis
for data-driven improvements and an important resource for
registry-based research. The clinical registers are independent
of, albeit to variable degrees linked to, the national cancer
registries and these data sources are complementary, each
with their strengths relative to the aims, design and pur-
poses of a study. Whereas the cancer registries are preferred
sources for studies of cancer incidence and prevalence, the
clinical registries contain more detailed data for assessment
of diagnostic paths and principles, treatment patterns, prog-
nostic factors, outcome and late effects. Clinical registry data
may be particularly relevant in areas where evidence from
randomized studies is lacking and where population
approaches are relevant [6–9]. Nation-wide coverage, high
completeness rates and possibilities for record linkage to
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other population-based registries allow for comprehensive
investigations and subgroup analyses.
We review the development and implementation of can-
cer-related clinical registries in Denmark, Norway and
Sweden with a focus on similarities and differences e.g., in
organization, administrative support, selection of quality indi-
cators, principles for reporting and follow-up, inclusion of
patient-reported measures, benchmarking and registry-
based research.
Setting and organization
Denmark, Norway and Sweden have a long tradition of col-
laborative clinical trials and research studies, motivated by
limited-sized populations and similar health care systems.
The countries are recognized as a stronghold for epidemio-
logic research based unique personal identifiers that allow
for record linkage within population-based registry networks
[10]. Specialized care is largely public and provided by 5
regions in Denmark, 4 health trusts in Norway and by 21
regions in Sweden. All three countries have national cancer
plans or strategies that are defined by the central govern-
ments and surveilled by the health authorities. State-of-the
art cancer care, from diagnostics through treatment, follow-
up, rehabilitation and palliative care, is defined in regularly
updated national guidelines with responsibility from national,
multidisciplinary and multi-professional expert groups. In
2008, Denmark was the first country to standardize and
expedite diagnostic paths through 29 cancer care pathways
that define investigations and define maximal lead times.
Similar systems have since 2015 been implemented also in
Norway and Sweden [11,12]. The organizations and responsi-
bilities for the clinical cancer registry initiatives differ some-
what between Denmark, Norway and Sweden.
In Denmark there are 25 clinical registries devoted to spe-
cific cancer diagnoses or groups of malignancies (Table 1).
The registries are regulated by the government and man-
aged by the Danish Clinical Quality Program and Clinical
Registries (RKKP). The registries are authorized by the Board
for Health Data and should respond to criteria for national
coverage and contribution to quality development (Table 2).
Denmark does not have a formal registry certification system,
but the registries and their variables are reviewed and cate-
gorized with consideration of factors such as interdisciplinar-
ity, health care sectors involved, clinical effect, links to
clinical guidelines, data coverage and research potential
every third year. At present, 4 cancer-related clinical registries
have reached the highest category. In Denmark, the Board of
Health and Welfare defines an overall plan for responsibilities
in cancer treatment and defines standards in select areas,
e.g., side-effects after surgery for breast cancer and rehabili-
tation following treatment for prostate cancer. The broader
responsibility to define and update clinical guidelines rests
with 24 national multidisciplinary groups with members
endorsed by various professional organizations. These multi-
disciplinary groups act as steering groups for the clinical
registries and also engage in research within their respective
areas of expertise. The steering groups advice on the opera-
tions, review, define and update quality variables and
approve data access. The RKKP is responsible for the stra-
tegic direction, technical competences, data handling, quality
control, basic statistics and epidemiologic analyses and deliv-
ers data for quality evaluations and research projects.
In Norway 8 clinical registries for cancer have been
awarded national registry status (Table 1). Certification has
until now been in four categories defined by documentation
and routines, coverage, completeness, reporting, develop-
ment plan, use of registry data for research. The 8 cancer-
related registries are placed in the second highest category.
Recently, additional criteria have been implemented to evalu-
ate registry-based quality improvements (Table 2). The
Cancer Registry of Norway (CRN) is responsible for the
administration of the clinical cancer-related registries, includ-
ing data storage, approvals of data access, statistical analyses
and annual reports. Each registry is assigned a quality assist-
ant at the CRN and has an advisory board to which regional
members are appointed by the regional health trust leader-
ships. The advisory groups define and review variables and
provide advice to the CRN on data access and registry
development.
In Sweden the 30 cancer-related clinical registries are for-
mally run through the Swedish Association of Local
Table 1. Overview of the cancer-related clinical quality registries in Denmark, Norway and Sweden.
Responsibilities and provisions Denmark Norway Sweden
Data custodian Danish regions Norwegian health funds Swedish regions
Responsible body/authority National Board of Health Data Cancer Registry of Norway the Swedish Association of Local
Authorities and Regions
Registry organization the Danish Clinical Quality Cancer Registry of Norway Regional Cancer Centers
Program and Clinical Registries
Fraction of all registries related to cancer diagnoses 25/88 8/54 30/106
Registries startup years 1977–2013 1993–2013 1997–2016
Cancer screening registries 3 2 3
Responsibility for endorsement of steering group Professional organizations Regional health care trusts Swedish Regions
Standardized annual report partly yes yes
Quality parameters at hospital level yes yes yes
Interactive online reports no planned yes
Quality data in patient format no yes partly
Future development plan and parameters defined no yes partly
Patient-representation in steering groups partly no yes
Patient-reported data in clinical registries partly partly partly
English summaries available no yes partly
Gradually rolled out, at present available for 23 registries.
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Authorities and Regions to which the quality registry steering
groups report (Table 1). The responsibility for the daily
administration of the registries is shared between the six
Regional Cancer Centers (RCCs). A certification system deter-
mines the yearly funding and possibilities for development
of content variables and functionalities. Registries are certi-
fied in three categories based on completeness, timeliness,
validity, use for quality improvement, innovation and
research output (Table 2). At present, 4 cancer-related regis-
tries are certified at the highest level. Registries not yet for-
mally certified should have a development plan and should
be linked to a RCC. The registry steering groups define and
review variables, contribute to various types of data reports
and evaluate and approve applications for data access. These
groups have strong links to the national multiprofessional
groups responsible for standards of care to ensure coordin-
ation between clinical guidelines and quality indicators.
Administrative and analytical services are provided by the
RCCs that, under the leadership of a national quality registry
coordinator, provide a framework for coordinated database
development and administrative and statistical support.
In all three countries the coordinating registry organiza-
tions, i.e., the RKKP in Denmark, the CRN in Norway and the
RCCs in Sweden strive to find an optimal balance between
ambitions and available resources to support data collection,
validate of content, development of technical solutions, com-
munication of the results to different target groups and
stakeholders and support for quality improvement initiatives
based on clinical registry data.
Data capture
The heath care regions/facilities are the formal data custo-
dians and are responsible for collecting data and monitoring
data quality. The steering/advisory groups suggest and
define quality variables in collaboration with the registry
organizations that also implement changes following
approval by the governing bodies. In Denmark and in
Norway, the registries largely receive data through auto-
mated transfer, though information on treatment and follow-
up, e.g., radiotherapy, oncology medicines, and patient-
reported outcome (PRO) partially require manual report-
ing [13].
In Denmark, variables from e-health systems and national
population-based registries such as the Patient Registry, the
Pathology Registry, the Causes of Death Registry and the
Central Person Registry are automatically transferred. There is
no formal link to the Danish Cancer Registry, which is under
the responsibility of the Health Data Authority. This pre-
cludes use of the Cancer Registry e.g., to monitor




1 Criteria for national status, method description for variables and completeness, defined quality indicators, describes
relevant analyses to reach aims, describes report formats for relevant groups, has established routines for data capture,
annual report, updated development plan
2 as #1 þ secures data from all health regions, presents quality indicator on national level, has a plan for analyses of
completeness, has a plan for analyses and reports of results at unit-level to participating units, updated
development plan
3 as #2 þ documents completeness of quality indicators, documents completeness of minimum 60% during the two recent
years, annual interactive presentation of quality indicators on the website www.kvalitetsregistre.no, provides
participating units with own aggregated and national data, presents participating units’ compliace with the most
important clinical guidelines, updated development plan
4 as #3 þ has documented correct and reliable data during 5 years, documents completeness of minimum 80% during the
two recent two years, provides participating units with personalized results and aggregated national results, uses data
scientifically, presents PROM/PREM
Quality improvements
C Does not fulfill the requirements for level B.
B Documents results based in quality improvements initiated within three years. These initiatives should be based on
registry data.
A Documents identification of areas for improvement and initiated or continous patient-related quality improvements.
Denmark No formal certification system applies. For authorization the registries should have regional or national coverage, should
contribute to development of quality in health care, should define inclusion and exclusion criteria and should be
supported by relevant professional groups.
The registries are reviewed and categorized every third year with consideration of e.g. interdisciplinarity, health care
sectors involved, clinical effect, links to clinical guidelines, data completeness and research potential.
Sweden
3 Tested, reliable data collection, preliminary analyses and development, basic on-line data reports, work to develop data
report functions, adheres to national standards, data validation plan, plan for user/patient collaboration, annual report,
variable list.
Data of high quality and a plan for reaching level 2 within 4 years.
2 Completeness of a minimum 60%.
1 Completeness above 85%.
Validation of data quality, including analysis of missing data. Should report a plan to the Medical Research Council with
tools for how to search and match information on a meta level.
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completeness and to distinguish between incident and recur-
rent tumors.
In Norway, all clinical notifications are collected through a
national portal to which all 10 radiotherapy units also pro-
vide data with high completeness. The pathology reports are
not yet fully standardized and predominantly manually
coded at the Cancer Registry. The CRN also collects informa-
tion on country of birth through links to the population
registry. Standardized linkage to 8 population registries, e.g.,
the Causes of Death Registry, the national Patient Registry
and the Population Registry, are performed on a monthly
basis to validate and enrich clinical registry data.
In Sweden, data are largely entered manually though
ongoing initiatives automated data transfer from e-health
systems. The mandatory reporting of cancer notifications to
the national Cancer Registry is linked to the reporting to the
clinical registries, which allows estimates of completeness
and distinction between incident and recurrent tumors. Data
are regularly linked to the Population Registry and to the
Causes of Death Registry. Additional registry links to enrich
the data require specific approvals are typically carried out
within research and improvement projects.
Clinical variables and data quality
The clinical registries typically contain basic demographic
information with personal identifiers, tumor-related variables
and define a variable number of process-related (e.g., multi-
disciplinary treatment conference, preoperative radiotherapy,
radical surgery) and outcome-related (e.g., local recurrence,
survival measures, late side effects) variables (Table 3). Data
quality has several dimensions related to completeness, time-
liness, comparability and validity. Quality control occurs at
three levels; as part of central validation e.g., for personal
identifiers and hospital codes, as part of the administrative
curation of data at the registry organizations, e.g., for dates
and missing data, performed by the RKKP, the CRN and the
RCCs and as part of quality control studies of core variables.
Most cancer-related clinical registries have completeness
rates exceeding 95% when compared to registered diagno-
ses in the national cancer registries and in patient-adminis-
trative systems (Table 3) [14–26]. Differences in diagnostic
criteria and alternative treatment routes may explain missed
inclusion in the clinical registries. Based on links to national
patient registries, data on treatment and follow-up show
completeness rates of 81–98% [19,23]. In the startup phases
several registries showed suboptimal timeliness, but this
aspect has significantly improved in recent years and is fur-
ther supported by automated data transfer. Validation stud-
ies are crucial to improve data quality and detect differences
in coding systems and algorithms and incompatibilities
between different data sources. In the Swedish registries for
gynecologic cancer, breast cancer, prostate cancer and gas-
tro-esophageal cancer validation studies focused on core var-
iables in 400–800 patients have shown 82–91% agreement
on individual data point level, which demonstrates a need
for continuous quality assurance initiatives [17,20,24–26].
Comparability is at present only partially possible between
countries and diagnoses due to heterogeneity in choice of
variables and parameters. In this regard it is striking that the
Danish and the Norwegian registries for breast cancer define
10 quality indicators, compared to 35 in the Swedish registry,
that the acute leukemia registries in Denmark contain 23
indicators whereas that in Sweden has 3 and that the Danish
and Norwegian prostate cancer registries define 6–8 quality
indicators while the Swedish prostate cancer registry defines
68 (Table 3). The variability in parameters related to follow-
up and outcome can be exemplified from Denmark where
only two registries, in breast cancer and malignant melan-
oma, contain follow-up variables, 7 registries contain infor-
mation on recurrence and 20 registries contain a survival
measure. Outcome-related variables differ between the coun-
tries with 45% of the 337 variables in Denmark relate to out-
come, 34% of 86 variables in Norway and 7% of 455
variables in Sweden (Table 3).
Many clinical registries have been initiated as treatment
registries in surgical departments, which is reflected in a pre-
dominance of surgery-related variables and relatively few
variables in diagnostics, medical oncology, radiotherapy, fol-
low-up and rehabilitation. The scarcity of variables within
medical oncology implies that the possibility to follow e.g.,
access to, effects and side-effects of new medical treatments
through the clinical registries is limited. To meet these needs,
a registry module for cancer medicines containing 7 key indi-
cators has been developed and implemented in Sweden to
capture data on 23 prioritized cancer drugs. In Norway the
INSPIRE project aims to grant regular reporting on medica-
tions from the hospital-based systems. In Denmark, a
research project develops modules for oncologic drugs in
select registries, e.g., breast cancer, melanoma and renal can-
cer. Inclusion of rehabilitation-related parameters also differ
between diagnoses and represents an area where generic
solutions could be sought to benefit all registries. Data on
patients treated within clinical trials are collected by some
registries, but this information is neither consistently col-
lected nor broadly available. Lack of variables related to
rehabilitation has been identified as an area for develop-
ment. Though generic variables have been defined in
Sweden, implementation in the clinical registries has been
slow. Collection of patient-reported data also remains to be
defined and implemented in most clinical registries.
Report formats
Report formats are under continuous development to meet
the requirements of various target groups. Traditional regis-
try reports are diagnosis-specific and provide data overviews
on the indicators at hospital and regional levels. Such annual
reports are generated with support from the registry centers,
i.e., RKKP in Denmark, the CRN in Norway and the RCCs in
Sweden. The support from the registry centers contribute to
an increasing streamlining of statistical methods, analyses
and data visualization formats with e.g., tables, bar charts,
funnel plots, trend analysis and hospital ranks. In recent
years there has been an increased focus on user-friendly

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































report formats, which are likely to raise interest and stimulate
engagement in quality work based on registry data. In
Denmark, the RKKP has, in collaboration with the Danish
regions and patient organizations, developed a quality man-
ual support data quality work and data-driven actions. In
Norway, the CRN provides standardized annual reports with
an attractive and reader-friendly format. In Sweden, score-
board formats are used across various registries to provide
decision-makers with snapshots of nationally prioritized key
performance indicators. The annual reports are largely stand-
ardized and the RCCs are in a process of gradually rolling
out online accessible and user-designated reports. These
interactive reports will partly substitute the annual reports,
which will rather provide overviews and updates of ongoing
initiatives and developments [27].
Based on relevant information governance regulations
and approvals, the clinical registries can provide data at indi-
vidual, anonymized or aggregate levels to accommodate
researchers, health providers, authorities and the private sec-
tor. In all three countries, detailed data are primarily meant
for local and/or regional quality monitoring and improve-
ment initiatives. Such access requires log-in and is typically
granted to responsible health professionals who can view
data from their respective registry and hospital/region.
Researchers, independent investigators and media may
request more detailed data to allow independent analyses
for statistical purposes. Aggregate data may also be provided
from the clinical registries to the Life Science industry as has
been done for e.g., melanoma in Norway and prostate cancer
in Sweden. To support and safeguard such collaborations,
the Swedish Regions and Municipalities, have established a
frame agreement for how the Life Science sector can access
and use clinical register data.
Monitoring changing principles of care
Registry-based quality data is an important resource for qual-
ity monitoring of e.g., diagnostic principles, waiting times,
treatment patterns, implementation of new therapies, acute
complications, long-term side effects and outcome in differ-
ent clinical subgroups. Several clinical registries have col-
lected data for more than 10 years and thus enable studies
of the effects from modified principles of care. Increasing
survival rates have been documented in several tumor types,
but registry data have also shed light on developments that
call for attention e.g., advanced-stage diagnosis and increas-
ing death rates in melanoma and variable adherence to
active surveillance recommendations in prostate cancer
[28,29]. A series of studies have documented that provision
of care according to national guidelines positively influence
clinical outcomes. Effects from refined diagnostics, e.g.,
increasing use of preoperative MRI and improved quality of
pathology reports have been demonstrated to influence
resection rates, local recurrence rates and survival in e.g.,
breast cancer, colorectal cancer, gastroesophageal cancer
and melanoma [30–39]. In e.g., colorectal cancer, lung cancer
and urinary bladder cancer, registry data have been used to
demonstrate increasing survival rates in large cohorts
[30,34,39–42]. In renal cancer, altered principles of care,
including standardized histology reports, preoperative CT of
the chest, partial nefrectomy for patients with T1a tumors,
minimally invasive surgery and nephron-sparing procedures
have been documented and parallels improving survival
rates [22,43].
The effects of structural changes and implementation of
new treatment guidelines can be followed in the clinical regis-
tries. Registry data from Norway and Sweden show that an
increasing fraction of patients with colorectal cancer, gastroe-
sophageal cancer and urinary bladder cancer undergo surgery
at high-volume hospitals with fewer hospitals performing such
surgeries [30,36,44]. Information from clinical registries also
document that laparoscopic surgery for colorectal cancer and
early-stage cervical cancer is safe with favorable survival rates
[45,46]. Registry studies show that fertility-sparing versus rad-
ical surgery for stage I ovarian cancer result in excellent (98%)
5-year survival rates in both groups, albeit with fewer recur-
rences in the former groups [47]. Optimal management of
early-stage tumors is an area of debate where the registries
have provided relevant data on favorable results in early-stage
renal cell cancer and the use of transanal endoscopic micro-
surgery in T1 rectal cancer [28,48]. Clinical registry data can
also be applied to build prediction models based on complex
clinical information such as consultations, imaging, biomarkers
and tumor data, to define patient groups that can be spared
adjuvant treatment or need of intensified surveillance and/or
rehabilitation [49–55]. The similararities in registry structures
allow for pooling of data sets to reach sufficient power with a
recent example from colon cancer, where the impact from
anastomotic leaks was studied in close to 23,000 patients
from Denmark, Norway and Sweden with anastomotic leaks in
3.7% and an adverse effect on survival in stage III tumors [56].
A growing number of studies assess long-term effects and
complication rates. In lung cancer, the influence of comor-
bidities on more frequent treatment complications in men
has been reported [57]. In rectal cancer, a decreased rate of
local recurrences following refined surgery and preoperative
radiotherapy has been shown to come at a price of more fre-
quent bowel movements, increased rates of urinary and fecal
incontinence, a negatively influenced sexual function and
worse scores for global quality of life and social function
[58,59]. In gastroesophageal cancer, major postoperative
complications such as dyspnea, fatigue and nutritional prob-
lems have been documented in one-third of the patients
5 years after treatment [60]. In men with prostate cancer a
significantly elevated risk of serious adverse effects after
curative treatment has been demonstrated up to 12 years
after treatment [61]. Also risks of other late effects such as
second primary cancers and loss of working years have been
reported based on clinical registry data [62,63].
Data from the clinical registries may also be used to study
clinical parameters and outcome in tumor subsets and select
populations, e.g., the elderly, where evidence is limited. In
prostate cancer, clinical registry data from more than 19,000
men with high-risk tumors have shown that among men in
their 70’ies, only 10% in the age group 75–80 years received
radical treatment despite greater than 50% probability of 10-
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year remaining life expectancy [64]. Based on more than
15,000 patients with colon cancer above age 70, this patient
group was less often adequately staged prior to surgery,
were less likely to be discussed at a multidisciplinary team
conference, showed higher rates of emergency surgery and
lower rates of curative resections [65]. Clinical registries are
also highly relevant to study the impact of and effects from
geographical and socio-economic inequalities, e.g., related to
differences in cancer incidence and outcomes [66–69]. Such
studies have revealed geographical and socioeconomic dis-
parities in stage distribution and excess mortality in malig-
nant melanoma and suggest that highly educated patients
with gastroesophageal cancer patients are 1.5–3 times more
likely to be discussed at a multidisciplinary conference and
receive treatment with curative intention [70,71].
Clinical registries may also provide data that support and
motivate political initiatives. In Denmark, data from the clin-
ical registry for prostate cancer revealed unmotivated differ-
ences in treatment strategies despite national standards of
care and case discussion at multidisciplinary treatment con-
ferences. Based on these data, the Danish National Board of
Health revised the directives for risk assessment and patient
information with the aim to ensure correct case manage-
ment. In Norway the Colorectal Cancer Registry was used to
evaluate outcome after transanal total mesorectal excision
for rectal cancer with identification of higher anastomotic
leak rates and unfavorable local recurrence rates, which led
to a national recommendation against this surgical technique
[72]. In Sweden and in Norway, clinical registries have been
used to verify low case volumes for e.g., penile cancer and
sarcoma, which has supported treatment centralized to
national expert centers [73]. In e.g., penile cancer these initia-
tives have been shown positive effects e.g., on surgical com-
petences at the specialist centers, reduced waiting times and
adherence to clinical guidelines.
Clinical registries may also be used to support precision
medicine approaches. In Sweden, an ongoing project devel-
ops a generic model for how registry data can support indi-
vidualized clinical decision-making through ‘patient
overviews’ [74]. Pilot projects have been run in the clinical
registries for kidney cancer, lung cancer and prostate cancer
where such modules have been implemented and provide
real-time data with a dashboard visualization of key clinical
data, an overview of the treatment history and patient-
reported outcome measures (PROMs) in graph format. The
clinical registries may also provide relevant for initiation of
individualized treatment initiatives [75]. The registries may
also support identification, inclusion and randomization of
patients in clinical trials. In Sweden, the ALASCCA trial on
adjuvant Non-Steroidal Anti-Inflammatory drugs uses a ran-
domization platform in the registries for colon cancer and
rectal cancer for study inclusion.
Benchmark studies
The clinical registries are also used to investigate differences
in outcome between regions or care providers, benchmark
hospitals and promote data-driven investigations of observed
variations [18,76–78]. Studies of risk profiles, diagnostic strat-
egies, treatment patterns and principles for follow-up
between different geographical regions and countries, how-
ever, require alignment of variables and indicators, which is
only partly possibly at present. We have collected examples
of comparable indicators and target levels in the clinical
registries for breast cancer, lung cancer and colorectal cancer
to demonstrate limited overlap and variable target levels for
many parameters (Table 4). In ovarian cancer comorbidity
has been suggested to explain differences in survival
between Danish and Swedish patients with better outcome
in the latter country [79]. To test this hypothesis, more than
3,100 patients from the Danish and Swedish Gynecologic
clinical registries were studied with demonstration of com-
parable comorbidities. Though concomitant diseases nega-
tively influence survival, this parameter could not explain the
observed survival differences between the countries [80].
The RKKP in Denmark, the CRN in Norway and the RCCs
in Sweden contribute to benchmarking studies with in-
depth analyses aimed at investigating and explaining dif-
ferences in patient outcome between subsets of patients
and between different regions and countries. Some regis-
tries have aligned their process indicators with inter-
national guidelines, e.g., the Swedish and the Norwegian
breast cancer registries that aligns several varaibles and
target levels with the EUSOMA guidelines [81,82]. In
Denmark, clinical registry data also contribute to
European benchmarking initiatives such as EURECCA, EU-
MELACARE and EPID and have documented treatment
variability, survival patterns and outcome in specific sub-
sets such as elderly patients [83,84].
Rare cancers
Collaborative initiatives are particularly important and
relevant in rare cancers, but despite a Scandinavian trad-
ition for clinical collaborative initiatives, the countries
have taken different and non-coordinated approaches to
the establishment of clinical registries in this area (Table
3) [85–89]. This can be exemplified by the clinical regis-
tries for penile cancer, anal cancer, eye tumors, mesotheli-
oma and sarcoma. In Sweden and Norway, anal cancer is
registered in a sub-registry of the colorectal cancer regis-
try, but this diagnosis is not registered in Denmark.
Sweden is the only of these countries that register meso-
thelioma as part of the lung cancer registry. The penile
cancer registries are free-standing clinical registries in
Sweden and Denmark, with the Danish registry discontin-
ued from 2020, whereas this diagnosis is not covered by a
clinical registry in Norway [90]. Eye tumors are registered
in a specially dedicated registry in Denmark, whereas
these diagnoses are not registered separately in Norway
and Sweden.
All three countries have sarcoma registries based on a
long-standing collaboration on clinical studies and research
initiative within the Scandinavian Sarcoma Group [87]. Yet,
the development of clinical registries for these tumor types

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































opportunity for collaborative studies. In Denmark, sarcomas
at different locations are collected within one registry.
Norway has a sarcoma registry that has not yet been
included in the national registry initiative. Sweden has separ-
ate registries for bone and soft tissue sarcoma and for vis-
ceral sarcomas, whereas gynecologic sarcomas are registered
within the endometrial cancer registry. In Sweden and
Norway development of the sarcoma registries is hampered
by lack of funding from the national registry initiatives. The
possibility of collecting, studying and reporting patterns of
disease, treatment and outcome for rare cancers in a truly
population-based setting has a particularly strong potential
in the Nordic setting with a joint population of 27 million
and similar environments for registry-based research.
However, this requires joint action and coordinated design
and selection of quality indicators.
In Scandinavia, long-term professional collaborations in
pediatric oncology, largely coordinated by the Nordic Society
of Pediatric Oncology and Hemathology (NOPHO), serve as a
model for how coordinated efforts to develop and compat-
ible registries, design and run clinical trials, define treatment
standards and study late side effects have had positive
effects on survival and quality of life [91–94]. In Denmark
and Norway, the childhood cancer registry is part of the
national clinical registries and in Sweden work is ongoing to
migrate 8 separate childhood cancer registries into the
Swedish national platform for clinical registry work [95].
Patient-reported measures
The introduction of PROM and patient-reported experi-
ence measures (PREM) currently receives much attention
in cancer care and may contribute to identification of risk
factors and protective factors for long-term outcome and
increase our understanding of quality of life aspcts.
Although a multitude of instruments to capture quality-of-
life and patient experiences have been developed, only a
few clinical registries have implemented PROM and PREM
measures, e.g., the non-melanoma skin cancer registry in
Denmark, the Norwegian clinical registry for prostate can-
cer and the Swedish registries for brain tumors, acute leu-
kemia, pancreatic cancer and prostate cancer. In Norway,
a pilot study collects PROM data from in three cancer
types in a separate health registry with inclusion of data
also from age-matched controls. PROM should be
designed in response to defined purposes to collect rele-
vant and timely data [96,97]. In prostate cancer, such
measures have revealed frequent adverse effects, which
most commonly relate to erectile dysfunction and sexual
inactivity, but also negatively influence urinary incontin-
ence, bowel disturbances and overall quality of life in 14%
that may provide an important basis for choice of therapy
and further refinement of future treatment principles
[98,99]. In the Swedish prostate cancer registry PREM data
have demonstrated a high degree (74%) of satisfaction
with care with participatory care, high-quality information,
and access to a nurse navigator defined as success fac-
tors [100].
Patient involvement
Patient involvement is a cornerstone in the work of the
Scandinavian clinical registries, but has been implemented in
various ways in the countries and the in registries. Patient
participation in the clinical registry steering groups is focused
at obtaining input on relevant measures, sharing and com-
municating data and discuss quality reports. In Denmark,
patient representation is in the process of implementation
with patient representation in a growing number of registry
steering groups. In Norway, patient involvement is organized
through annual meetings with patient organizations. The
registry center organizations also include patient representa-
tives in their advisory boards and arrange annual patient
panel meetings. National patient organizations are notified
about annual reports though targeted communication initia-
tives. In Sweden, patient representation in registry steering
groups has been established since several years. The devel-
opment of instruments for open and easy access to real-time
quality data can positively contribute to the public debate,
but also underscores needs for presentation formats
designed for laymen. In order to facilitate interpretation of
data, all stakeholders and end-user needs should be consid-
ered and in this regard training is relevant for all parties; for
patient representatives related to data interpretation and
benchmarking and for health professionals related to
patient-centeredness [101].
Challenges and future developments
The clinical registries in Denmark, Norway and Sweden have
provided cancer care with an extensive and comprehensive
set of quality indicators that allows surveillance of quality
and equity in care. The registries are at a point in their
development where high completeness rates and data
maturity allow for population-based assessment of patterns
of care and long-term outcomes. However, maximized return
on investment for quality assurance, health care develop-
ment and research purposes depends on further develop-
ments related to data quality and harmonization of variables
and indicators, efficient data links, data sharing and compre-
hensive and attractive reporting formats.
Harmonized variables and common standards
In the clinical cancer registries, data completeness is good
to excellent for variables related to inclusion, diagnostics
and surgery, whereas several registries need to improve
the inclusion and quality data on variables related to
oncology, rehabilitation and patient-reported parameters.
Lack of standardization and definition of relevant varia-
bles represent barriers for collaborative and comparative
studies. This can be exemplified by similar, but non-identi-
cal, variables in the registries for breast cancer, colorectal
cancer and lung cancer (Table 4). To monitor the provi-
sion of cancer care, the registries need to be enriched by
updated information on socioeconomic indicators, include
quality indicators that cover the entire patient trajectory
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as well as patient-reported outcomes [102]. The clinical
registries would also benefit from harmonization of defini-
tions and reporting standards with the national cancer
registries to ensure comparable results and efficient man-
agement of both types of registries.
Research and data sharing
To utilize the full potential of the clinical registries, steering
groups, researchers and decision-makers in health care need
to accelerate registry initiatives, not least related to simplified
and expedited data sharing and intensified research ambi-
tions. Generation of new evidence typically requires record
linkages between registries and data sharing not only to
address key questions, but also to evaluate quality develop-
ment initiatives. In reality, such record linkage is increasingly
complex and time-consuming due to long handling times,
variable requirements for documentation and divergent
interpretations of the General Data Protection Regulation
(GDPR) for data sharing and data transfer [97]. Another obs-
tacle is long handling times in registry steering groups, at
the responsible Registry Centers or at the National author-
ities that oversee and administer linkage to national health
population databases.
Data sharing remains complex between the Nordic coun-
tries, partly because of challenges in the interpretation of EU
standard contract on part of countries’ or institutions’ legal
representatives. This has led to registry copies in research
database format enriched with data on e.g., comorbidity,
socioeconomic factors, treatment, side-effects, migration and
causes of death from other relevant registries. Though feas-
ible for research purposes this development requires rela-
tively large resources and intermittent data updates with a
risk of generating parallel systems for clinical improvement
initiatives and research purposes. Initiatives that map registry
variables and provide overviews in toolbox format are under-
way in Sweden and Denmark. Further, NordForsk under the
Nordic Council of Ministers supports Nordic collaborative
research, research infrastructures and also investigates possi-
bilities for a fellow Nordic IT infrastructure to share
health data.
With a common basis in publicly funded health care sys-
tems, the clinical registries can provide unique insights into
the determinants and effects on health disparities and under-
served populations. In these areas, the clinical registries
could provide highly relevant information and insights pro-
vided data linkage to information on education and income,
currently available through the national bureaus of statistics,
is possible.
Another obstacle to achieve the full potential of the clin-
ical registries is limited funding for clinical and epidemiologic
research, which restricts efficiency e.g., through lack of sup-
port for data managers and statisticians. To stimulate
research in this area and to introduce a new generation of
scientists the Association of the Nordic Cancer Registries has
initiated a research school in epidemiology, which integrates
education in epidemiologic research methods and cancer
surveillance with individual project work.
Comprehensive cancer care quality reports
An important aspect to stimulate interest in and usage of
the clinical registries as a means to develop quality of cancer
care is easy access to close to real-time, user-designated and
comprehensive out-data formats aimed at various target
groups such as decision-makers, health care leaders, health
professionals and patient representatives.
Recommendations to accelerate registry-based
health care improvements
To support and stimulate usage of the clinical registries for
evidence-based health care improvements, we suggest that
Responsible authorities:
 Promote and disseminate registry-based data through
real-time data and comprehensive overviews of quality
performance
 Request data validation and harmonization of variables
and ensure relevant interaction between the cancer regis-
tries and the clinical registers in cancer
 Engage in solutions for efficient administrative processes
for data extraction and reduce barriers for data sharing
and transfer between the Nordic countries
 Actively involve patients and public in the registry
initiatives
 Contribute to educate a new generation of scientists in
registry-based research, epidemiology, data management
and biostatistics
Health care leaders and quality managers:
 Regularly monitor clinical registry parameters, request
data on data validity, provide regular feed-back on
achievements, follow improvement initiatives and link
these to transparent structures for responsibilities to
implement relevant changes
 Support registry-based research and contribute to dissem-
ination of relevant findings
Registry steering groups and registry organizations:
 Actively promote the potential of the clinical registries for
health-care improvement and lead by good example
through establishment of comprehensive regis-
try overviews
 Develop principles for validation and continuous quality
assurance, including provision of variable definitions and
information on data quality in the various registries
 Secure transparent processes for data access and efficient
processes for data extraction and transfer
 Work to harmonize quality variables between diagnoses
and countries to allow comparison and collaborative stud-
ies and facilitate benchmarking, e.g., related to variables
for rehabilitation and patient-reported outcomes
 Ensure inclusion of variables that reflect the entire patient
trajectory, including performance in diagnostics, data on
various treatment types and new medicines, rehabilitation
and patient-reported outcomes
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 Prioritize development of real-time, user-designated, inter-
active registry reports
 Consider how key socioeconomic parameters can be cap-
tured to provide data on equity of care
 Establish research plans for all clinical registries
Patient organizations:
 Demand open, real-time and accessible quality data and
engage in reviewing and discussing results based on
these to contribute to a strengthened focus on quality
of care
 Request inclusion of relevant patient-reported out-
come variables
Conclusions
The clinical registries related to cancer in Denmark, Norway
and Sweden are receiving increasing attention based on
broad coverage, high completeness and levels of maturity
that allow for comprehensive analyses and impactful studies.
Over the years, key performance indicators have been opti-
mized, report formats improved and the registries have been
used to answer clinically relevant questions, document
improvements in care and define areas for targeted interven-
tion. At the same time, the potential to use of registry data
for strategic decisions, quality improvement and research is
not fully utilized. Further work is needed to ensure validity,
harmonize variables, ensure parameters throughout the
patient trajectory and allow for more efficient access and
sharing of data. The many recent development in the can-
cer-related registries related to at-glance overviews of the
quality landscape and user-friendly, personalized real-time
data access will likely increase interest in as well as outcome
of the Nordic registry initiatives for different stakeholders –
from health professionals and leaders to patient advocates
and decision-makers. The clinical registries have contributed
to better quality of cancer care in the Nordic countries, but
need further nursing to continue to fill important knowledge
gaps and meet future needs.
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